



Switching to CRISPR– Cas Systems from Uncultivated Microbes

September 2018

Mike Fan

Report Code: BIO172A

Table of Contents

- CRISPR Cas Genome Editing: Therapeutic or Thwarted by Preexisting Human Immunity? 1
- Immunogenicity Risk..... 3
 - Potential Solutions to Overcome Preexisting Immunity to Cas Proteins in Humans..... 4
- Oncogenicity Risk 7
 - Potential Solutions to Overcome Oncogenicity Risk 8
- What Could Happen Next? 9
 - Scientific Community..... 9
 - Investors 10
 - Regulatory Societies 11
- What to Expect in the Market?..... 12
- A Note from the Editor 15
- Analyst’s Credentials..... 17

- [About BCC Research..... 19](#)
- About BCC Research..... 20
- BCC Membership 20
- BCC Custom Research 20